Home FDA labels a6ac8312-61c4-4783-b6ae-6ad1abe11979 FDA label a6ac8312-61c4-4783-b6ae-6ad1abe11979 openFDA label record# This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)
SPL set ID 4bc21802-42b1-4f64-945d-9a10182ddec1
SPL ID a6ac8312-61c4-4783-b6ae-6ad1abe11979
Version 3
Effective date 2010-10-06
Source export date 2026-11-13
Source partition 6
Source file https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run 20261116T150851Z
Imported at 2026-11-16 16:26:56
Harmonized identifier links# Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
Harmonized identifiers page 1 of 1 · 2 matching rows.
Adverse reactions cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions sections page 1 of 1 · 1 matching rows.
adverse reactions ADVERSE REACTIONS The major adverse reaction reported to date with BREVOXYL ® -4 Creamy Wash and BREVOXYL ® - 8 Creamy Wash therapy is irritation of the skin including erythema, burning, peeling, dryness, and pruritus. This is reversible when treatment is reduced in frequency or discontinued. Dermatitis and allergic contact dermatitis including face edema may occur.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.